We are live on ! Find out more
BVF Inc

BVF Inc Portfolio holdings

AUM $3.04B Turnover 10.42%
1-Year Est. Return 129.63%
This Fund
S&P 500
This Quarter Est. Return
-17.58%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$495M
AUM Growth
-$71.6M
Cap. Flow
+$24.8M
Cap. Flow %
5.02%
Top 10 Hldgs %
75.58%
Holding
34
New
4
Increased
11
Reduced
4
Closed
7
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.3 years

Sector Composition

Rank Sector Weight
1 Healthcare 87.19%
2 Miscellaneous 12.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$806M
$50.8M 10.26%
5,820,001
+3,227,698
+125% +$30.1M
2013 Q2
9 quarters
CCXI icon
2
DELISTED
ChemoCentryx
CCXI
$45.8M 9.26%
7,573,493
+303,480
+4% +$2.19M
2013 Q2
9 quarters
CASC
3
DELISTED
Cascadian Therapeutics
CASC
$44.8M 9.06%
2,726,756
+1,101,060
+68% +$22.6M
2013 Q2
9 quarters
ARRY icon
4
DELISTED
Array Biopharma
ARRY
$44.1M 8.92%
9,680,630
+511,354
+6% +$3.03M
2013 Q2
9 quarters
CNCE
5
DELISTED
Concert Pharmaceuticals
CNCE
$42.3M 8.55%
2,255,168
-266,284
-11% -$4.53M
2014 Q3
4 quarters
BPMC icon
6
DELISTED
Blueprint Medicines
BPMC
$36.3M 7.34%
1,702,654
+120,246
+8% +$3.33M
2015 Q2
1 quarter
LOXO
7
DELISTED
Loxo Oncology
LOXO
$26.8M 5.41%
1,531,108
-83,973
-5% -$1.64M
2014 Q3
4 quarters
VTAE
8
DELISTED
Vitae Pharmaceuticals
VTAE
$26.2M 5.28%
2,375,933
+771,318
+48% +$8.2M
2014 Q3
4 quarters
FWP
9
DELISTED
Forward Pharma
FWP
$23.9M 4.84%
145,189
+1,049
+0.7% +$220K
2014 Q4
3 quarters
OMED
10
DELISTED
OncoMed Pharmaceuticals
OMED
$22.8M 4.61%
1,376,113
+111,398
+9% +$2.23M
2013 Q3
8 quarters
CTIC
11
DELISTED
CTI BioPharma
CTIC
$14.6M 2.95%
+1,000,000
New +$17.3M
2015 Q3
0 quarters
CYTK icon
12
Cytokinetics
CYTK
$7.2B
$14.1M 2.85%
2,106,989
– –
2013 Q2
9 quarters
ARQL
13
DELISTED
Arqule
ARQL
$12.3M 2.48%
6,566,148
+135,440
+2% +$234K
2013 Q2
9 quarters
TBRA
14
DELISTED
Tobira Therapeutics
TBRA
$11.4M 2.29%
1,175,233
– –
2013 Q3
8 quarters
QLTI icon
15
DELISTED
QLT Inc
QLTI
$9.9M 2.01%
3,737,446
– –
2013 Q2
9 quarters
XENE icon
16
Xenon Pharmaceuticals
XENE
$3.81B
$8.55M 1.73%
1,035,572
+356,808
+53% +$3.54M
2014 Q4
3 quarters
ONCT icon
17
DELISTED
Oncternal Therapeutics
ONCT
$8.19M 1.65%
7,695
– –
2014 Q4
3 quarters
GYRE icon
18
Gyre Therapeutics
GYRE
$499M
$4.76M 0.96%
9,074
+623
+7% +$950K
2013 Q2
9 quarters
SVRA icon
19
Savara
SVRA
$988M
$2.96M 0.6%
72,915
-103
-0.1% -$3.29K
2014 Q4
3 quarters
CALA
20
DELISTED
Calithera Biosciences
CALA
$2.48M 0.5%
+22,825
New +$2.96M
2015 Q3
0 quarters
VIRX icon
21
DELISTED
Viracta Therapeutics
VIRX
$2.02M 0.41%
+11,905
New +$4.3M
2015 Q3
0 quarters
GBIM
22
DELISTED
GlobeImmune
GBIM
$1.77M 0.36%
678,400
– –
2015 Q2
1 quarter
FLNA icon
23
Filana Therapeutics
FLNA
$24.2M
$1.7M 0.34%
+132,680
New +$1.67M
2015 Q3
0 quarters
VXRT icon
24
DELISTED
Vaxart
VXRT
$695K 0.14%
31,889
– –
2014 Q1
6 quarters
APTO
25
DELISTED
Aptose Biosciences
APTO
$179K 0.04%
92
-142
-61% -$316K
2014 Q4
3 quarters

Similar funds

BVF Inc's Q3 2015 Portfolio in Review

As of Q3 2015, BVF Inc held 34 positions worth $495M, down 13% from $567M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

BVF Inc deployed $24.8M of net new capital in Q3 2015, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was CTI BioPharma: 1,000,000 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Concert Pharmaceuticals, an estimated $4.53M trimmed.

  • BVF Inc's largest Q3 2015 buy was CTI BioPharma: 1,000,000 shares worth $14.6M.
  • BVF Inc added most to Ironwood Pharmaceuticals in Q3 2015, an estimated $30.1M increase.
  • BVF Inc's biggest Q3 2015 reduction was Concert Pharmaceuticals, cutting an estimated $4.53M.
  • BVF Inc fully exited Exelixis in Q3 2015, selling an estimated $10.4M.
  • BVF Inc's ten largest holdings make up 76% of its $495M portfolio in Q3 2015.
  • BVF Inc opened 4 new positions and closed 7 in Q3 2015.
  • BVF Inc's portfolio value fell 13% quarter-over-quarter to $495M.

Based on BVF Inc's 13F filing for Q3 2015, filed 16 Nov 2015.